A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214

Trial Profile

A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2015

At a glance

  • Drugs ITI 214 (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 18 Feb 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 28 Jul 2014 Planned number of patients changed from 64 to 76 as reported by ClinicalTrials.gov.
    • 24 Feb 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top